HomeBUSINESS
BUSINESS

Astellas Looks to Be First to Market in HIF-PH Inhibitor Space
(Aug.8.2017)

Chihiro Yokota, Head of Japan-Asia Development, Development (right), Yuzuru Komano, vice president, Japan-Asia Clinical Development 2
Astellas Pharma is pinning its hopes on its next generation renal anemia treatment roxadustat to help offset major US patent expiries looming in 2019, aiming for its launch as the first drug in a class of medicines called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors ...
(LOG IN FOR FULL STORY)

News Calendar